DIRS.INFO The most relevant business & tech news

— Lisa Kailai Han 7:07 a.m. — Lisa Kailai Han 6:48 a.m. "At current levels, we believe the risk/reward skews to the downside," wrote analyst Paul Lejuez. — Lisa Kailai Han 6:05 a.m. — Lisa Kailai Han

Persons: Robert Ford Aguilar, Aguilar, Lisa Kailai Han, Rachel Vatnsdal, GeoMx, Vatnsdal, skews, Paul Lejuez, — Lisa Kailai Han, Nik Modi, Raymond James, Matt Roberts, headwinds, Roberts, Ashwani Verma, Verma, Morgan Stanley, Micron Morgan Stanley, Joseph Moore's, Moore, Amit Mehrotra, Mehrotra, Sangita Jain, Jain, Fred Imbert Organizations: CNBC, Monday, UBS, Teva Pharmaceutical, Bloom Energy, Bank of America, Arcos Dorados Bank of America, Arcos Dorados, ARCO, JPMorgan downgrades, JPMorgan, U.S, District, Prognosys, 10X Genomics, Citi, RBC, RBC Capital Markets, UBS downgrades Jazz Pharmaceuticals, Jazz Pharmaceuticals, Digital, Micron, Western, Deutsche Bank, BE Locations: America, Caribbean, Argentine, Delaware, NSTG, U.S, Europe, Mondelez, narcolepsy

CAPE TOWN, South Africa (AP) — South Africa, Colombia and other countries that lost out in the global race for coronavirus vaccines are taking a more combative approach towards drugmakers and pushing back on policies that deny cheap treatment to millions of people with tuberculosis and HIV. The pills are especially important for South Africa, where TB killed more than 50,000 people in 2021, making it the country’s leading cause of death. In July, J&J’s patent on the drug expired in South Africa, but the company had it extended until 2027, enraging activists who accused it of profiteering. Back then, President Nelson Mandela’s government in South Africa eventually suspended patents to allow wider access to AIDS drugs. Bedaquiline was not rolled out as a standard treatment in South Africa until 2018.

Persons: they’ve, ”, Brook Baker, Johnson, Christophe Perrin, Peter Maybarduk, Petro Terblanche, Afrigen, Nelson Mandela’s, “ Mandela, Terblanche, Lynette Keneilwe Mabote, Andy Gray, Gray, Zolelwa, Bedaquiline, “, Sifumba, ___ Cheng Organizations: Health Organization, Northeastern University, One, Johnson, J, Viiv Healthcare, WHO, Public Citizen, Pfizer, Moderna, Terblanche, Big Pharma, South, University of KwaZulu, World Health Organization, AP Locations: CAPE, South Africa, Colombia, Belarus, Ukraine, Colombian, Washington, Africa, Natal, South African, London

☆ Macron to unveil 2.1 bln eur Novo Nordisk pharma investment in France
▼ + stars: | 2023-11-23 | by ( ) www.reuters.com time to read: +1 min

The logo of Danish drugmaker Novo Nordisk in their offices in Hillerod, Denmark, September 26, 2023. REUTERS/Tom Little Acquire Licensing RightsPARIS, Nov 23 (Reuters) - French President Emmanuel Macron will on Thursday inaugurate a 2.1 billion euro ($2.3 billion) investment by Danish pharmaceutical company Novo Nordisk (NOVOb.CO) in France, his office said, pitching it as a sign of newly restored French industrial competitiveness. The investment, for which no detail was provided by Macron's office, will be based in Chartres, west of Paris, where Novo already employs nearly 2,000 people. The Elysee palace deemed it the most significant investment in the health sector of Macron's mandates so far and said it would create 500 jobs. ($1 = 0.9168 euros)Reporting by Michel Rose, Editing by Dominique VidalonOur Standards: The Thomson Reuters Trust Principles.

Persons: Tom Little, Emmanuel Macron, Michel Rose, Dominique Vidalon Organizations: Novo Nordisk, REUTERS, Rights, Thomson Locations: Danish, Hillerod, Denmark, France, Chartres, Paris

The Supreme Court is set to hear arguments Dec. 4 over whether the agreement, part of the resolution of Purdue Pharma's bankruptcy, violates federal law. She initially opposed the deal with Purdue Pharma but has come around. The Purdue Pharma settlement would be among the largest. But in the decade before that, they were paid more than $10 billion, about half of which family members said went to pay taxes. The department and Purdue Pharma forged a plea bargain in a criminal and civil case.

Persons: Sackler, Ellen Isaacs ’, Ryan Wroblewski, ”, Mike Quinn, ” Lynn Wencus, Jeff, ” Wencus, It's, General Merrick Garland, Donald Trump, Joe Biden, Purdue Pharma’s, ” ___ Mulvihill Organizations: WASHINGTON, Purdue Pharma, Purdue, Sackler, Bankruptcy, Justice Department, Republican, Democrat, Congress, Boy Scouts of, Boy Scout, Catholic, “ Locations: Florida, Wrentham , Massachusetts, Stamford , Connecticut, ”, Boy Scouts of America, Cherry Hill , New Jersey

LONDON, Nov 23 (Reuters) - Leading scientists urged caution over fears of another pandemic on Thursday after the World Health Organization requested more information from China on a rise of respiratory illnesses and pneumonia clusters among children. It called for more information about "undiagnosed pneumonia - China (Beijing, Liaoning)". The standard wording of the alert echoed the first-ever notice about what would become COVID-19, sent on Dec. 30 2019: "Undiagnosed pneumonia - China (Hubei)." Both the WHO and China have faced questions over transparency during the early days of COVID. In China itself, there has been a lot of recent coverage of a rise in respiratory illnesses, including among children.

Persons: Marion Koopmans, COVID lockdowns, Brian McCloskey, Virologist Tom Peacock, Jennifer Rigby, Jo Mason, Christina Fincher Organizations: World Health Organization, WHO, COVID, International Society for Infectious, FTV News, Reuters, Imperial College London, Thomson Locations: China, Dutch, Beijing, Liaoning, Hubei, Taiwan

☆ Giving Thanks When the World is on Fire
▼ + stars: | 2023-11-22 | by ( Amanda Taub | ) www.nytimes.com time to read: +3 min

I am thankful that my children have never felt the pain of burying a beloved sibling. Thankful that if we needed a hospital, it would have electricity and sterile equipment and supplies like anesthesia available. Thankful that my children are alive. But also sad and angry that we live in a world where these things are blessings to be counted, and where so many cannot do so. I want to hear about things you have read (or watched or listened to) that have had the biggest impact on you this year.

Persons: Jenny Sidhu, Barbara Kingsolver, Beth Macy, Dopesick Organizations: Purdue Pharma Locations: Gaza, Israel, Lebanon, Rocklin, Calif

The lawsuit also alleged that Pfizer, despite knowing of the quality-control issues, persuaded Texas' Medicaid program to add Quillivant to its list of preferred drugs. The lawsuit accuses the companies of defrauding the state's Medicaid program, and seeks unspecified money damages from the companies. Pfizer and Tris, which manufactured the drug for Pfizer, did not immediately respond to a request for comment. The U.S. Food and Drug Administration in 2017 warned Tris of manufacturing lapses. Reporting by Brendan Pierson in New York, Editing by Alexia Garamfalvi and Matthew LewisOur Standards: The Thomson Reuters Trust Principles.

Persons: Dado Ruvic, Ken Paxton, Pfizer, Tris, Paxton, Quillivant, Tarik Ahmed, Brendan Pierson, Alexia Garamfalvi, Matthew Lewis Organizations: Pfizer, REUTERS, Texas, Tris, Republican, Nextwave Pharmaceuticals, U.S . Food, Drug Administration, Southern, of, Thomson Locations: Harrison County , Texas, Texas, U.S, Manhattan, of New York, New York

[1/5] Taiko Nakamura samples whisky barreled in the year he founded at his distillery in Shizuoka, Shizuoka Prefecture, Japan October 25, 2023. The explosion of craft whisky in Japan follows a boom and bust in the industry. Last week, Sotheby's offered what it claimed was the most valuable collection of Japanese whisky at auction, headlined by a 52-year old bottle that sold for 300,000 pounds ($373,830). Suntory, Japan's biggest and best-known whisky maker, recently invested 10 billion yen ($67 million) to upgrade its distilleries, including its Yamazaki site. "I believe we need to put all our effort into making Japanese whisky that lives up to the quality of the Japanese whiskies made by our predecessors," he said.

Persons: Rocky Swift, Suntory's, Taiko Nakamura, Long, whiskies, Sotheby's, Shinji Fukuyo, Casey Wahl, Kamui, Shizuoka's Nakamura, Miral Organizations: REUTERS, Suntory, trailblazer, Nikka, Asahi Group, Japan's, Japanese distillers, Diageo, IJW Whiskey, Nikkei, Thomson Locations: Shizuoka, Shizuoka Prefecture, Japan, Yamazaki, Scotland, Hong Kong, Japanese, Komasa Kanosuke, Kentucky, Hokkaido, American, Rishiri

Analysts attended earnings calls in the third quarter armed with questions for healthcare and consumer companies about the potential effect on their sales from the growing popularity of these drugs, known as GLP-1 agonists. A Reuters analysis of earnings transcripts for the third quarter showed "GLP-1" or alternatives like "obesity" or "weight-loss medications" were mentioned 256 times across 29 U.S. and European healthcare and consumer companies. That's more than double the mentions for the second quarter, when those phrases came up 127 times. While some consumer companies have talked about factors such as fewer calories being consumed, "these kind of large extrapolations" seem to be a bit of a stretch, said BMO Capital analyst Evan Seigerman. For big pharma manufacturers like Pfizer (PFE.N) and Amgen (AMGN.O), analyst questions were aimed at their obesity drug candidates.

Persons: Lilly, George Frey, Jeff Jonas, it's, Eli Lilly's, John Furner, Mondelez, Eli Lilly, Evan Seigerman, LVMH, Rajesh Kumar, Jonas, Bhanvi Satija, Savyata Mishra, Arpan Varghese, David Gaffen, Shounak Organizations: Novo Nordisk, Pharmacy, REUTERS, Gabelli, Novo, Walmart, Walmart U.S, Hershey, Truist Securities, Krispy, BMO Capital, Danish, pharma, Pfizer, Devices, HSBC, Thomson Locations: Provo , Utah, U.S, United States, Novo, Bengaluru

[1/5] A member of the teamLab digital art group poses in an installation in preparation for the reopening of their Borderless museum in February at the Azabudai Hills complex in Tokyo, Japan November 17, 2023. The name refers to digital art pieces that blend into each other and encourage guests to wander at their own pace. The relocation is part of Mori's strategy of placing cultural attractions in integrated business and residential projects. teamLab has developed a global reputation for its experimental and interactive set pieces that meld images and senses. Previous projects in Tokyo featured digital art mixed with a sauna experience and a laser light show enhanced performance of Giacomo Puccini's opera "Turandot."

Persons: Kim Kyung, Toshiyuki Inoko, Mori, Giacomo Puccini's, Inoko, Rocky Swift, Simon Cameron, Moore Organizations: REUTERS, Rights, Thomson Locations: Tokyo, Japan, Tokyo Bay, Mori's

☆ Obesity Drugs Put These Stocks on a Crash Diet—Now They’re Rebounding
▼ + stars: | 2023-11-17 | by ( David Wainer | ) www.wsj.com time to read: 1 min

Makers of medical devices were prepared for doom and gloom following a study of obesity drugs and cardiovascular health—but the bearish scenario hasn’t panned out. Photo: Catherine Ivill/Getty ImagesThere is a bit of cognitive dissonance in healthcare investing right now. After reviewing the highly anticipated results from a study of Novo Nordisk’s blockbuster obesity treatment Wegovy released over the weekend, cardiologists at a major medical meeting and the pharma crowd on Wall Street were broadly upbeat. “Today’s confirmatory results lay the groundwork for the coming paradigm shift of metabolic treatment,” gushed Evan Seigerman, an analyst at BMO Capital Markets.

Persons: Catherine Ivill, Novo, Wegovy, ” gushed Evan Seigerman Organizations: pharma, BMO Capital Markets

A sign is pictured outside an Eli Lilly and Company pharmaceutical manufacturing plant at 50 ImClone Drive in Branchburg, New Jersey, March 5, 2021. Incretins are peptide-based drugs such as Mounjaro that mimic gut hormones to suppress appetite and stimulate insulin secretion. Lilly said it had announced investments of more than $11 billion in global manufacturing in the past three years. Major production sites that Lilly runs outside of its U.S. home market are in Ireland, France, Spain, Italy and China. The new Alzey site will employ up to 1,000 highly skilled workers such as engineers, technicians and scientists, said Lilly.

Persons: Eli Lilly, Mike Segar, Lilly, Karl Lauterbach, Lauterbach, generics, Patrick Wingrove, Matthias Williams, Jason Neely, David Evans Organizations: Company, REUTERS, Rights, Reuters, U.S ., Novo Nordisk, European Union, pharma, The U.S ., Thomson Locations: Branchburg , New Jersey, Germany, Alzey, U.S, United States, Danish, Berlin, Fegersheim, France, European, Indiana , North Carolina, Limerick, Ireland, Spain, Italy, China, The U.S

☆ China is helping the US deal with its massive fentanyl problem — sort of
▼ + stars: | 2023-11-17 | by ( Matthew Loh | ) www.businessinsider.com time to read: +5 min

The US says China is a main source of materials for fentanyl that later ends up in America. The deal, which both leaders settled at the Asian-Pacific Economic Committee summit in San Francisco, would see Beijing assist Washington by regulating fentanyl precursors in China. The Drug Enforcement Administration has warned in recent years that China is a primary source for key ingredients in fentanyl. Advertisement"Focusing on China as the source of the problem has been because it's such an easy country to criticize," Ross said. For the Biden administration, the fentanyl deal has been an issue repeatedly pushed by US officials, Liu said.

Persons: —, Joe Biden, Xi Jinping, Zha Daojiong, Biden, Xi, Liu Zongyuan, Maurice R, Greenberg, Liu, Robert Ross, Ross, Eric Richardson, that's Organizations: Service, Pacific, Drug, Administration, Business, Peking University, pharma, of Foreign Relations, DEA, Boston College, UC Berkeley, INHR, United Nations, US, Bloomberg, Reuters, Forensic Public Security Institute Locations: China, America, San Francisco, Beijing, Washington, India, it's, Mexico, United, Europe, Xinjiang

The logo of Lilly is seen on a wall of the Lilly France company unit, part of the Eli Lilly and Co drugmaker group, in Fegersheim near Strasbourg, France, February 1, 2018. REUTERS/Vincent Kessler Acquire Licensing RightsNov 17 (Reuters) - Retail flows into Eli Lilly (LLY.N) spiked to a more than two-year high in November, as small investors rushed to buy the stock after the U.S. pharma major received a highly anticipated approval for its weight-loss drug Zepbound. Lilly and Novo Nordisk (NOVOb.CO) - seen as leaders in a potential $100 billion obesity treatment market - have helped rekindle retail investor interest in the healthcare sector. "During the COVID period, retail investors were piling into healthcare because of the vaccines and after that there was a bit of a hangover of purchases. Reuters GraphicsRetail investors are now "catching up" with institutional investors, said Sel Hardy, vice president of equity research at CFRA.

Persons: Lilly, Eli Lilly, Vincent Kessler, Zepbound, Marco Iachini, Hardy, JPMorgan Chase, Vanda, Ozempic, drugmakers, Iachini, Bhanvi Satija, Sriraj Organizations: REUTERS, U.S . pharma, Vanda Research, Novo Nordisk, Graphics Retail, Sel Hardy, JPMorgan, BlackRock, AMC, Thomson Locations: Lilly France, Fegersheim, Strasbourg, France, U.S, Bengaluru

CAIRO, Nov 16 (Reuters) - The United Nations is looking for ways to evacuate Al Shifa hospital in Gaza but options are limited by security and logistical constraints, a senior World Health Organization official said on Thursday. "We are looking at the case for full medical evacuation but there are a lot of security concerns, there are a lot of logistics constraints. Tents and shelters used by displaced Palestinians stand at the yard of Al Shifa hospital during the Israeli ground operation around the hospital, in Gaza City November 12, 2023. She said an ICRC medical convoy delivering supplies to a separate hospital in Gaza had come under fire last week. "It is difficult to answer how this would normally take place [medical evacuation in conflict], because this situation is anything but normal," she said.

Persons: Rick Brennan, Brennan, Ahmed El Mokhallalati, Mai ShamsElDin, Jennifer Rigby, Toby Chopra, Aidan Lewis, Christina Fincher Organizations: United Nations, World Health Organization, Palestinian, International Committee, WHO, Al, ICRC, Thomson Locations: CAIRO, Al Shifa, Gaza, Jerusalem, Egypt, Cairo, Gaza City, Shifa, Al Arish, Turkey

Japan's Prime Minister Fumio Kishida and Chinese President Xi Jinping pose for a family photo during Asia-Pacific Economic Cooperation (APEC) CEO Summit in San Francisco, California, U.S. November 16, 2023. They also pledged to hold high-level dialogue on economic issues and welcomed the launch of a framework to discuss export controls as they met on the sidelines of an Asia Pacific Economic Cooperation summit. In a joint statement in 2008, Japan and China agreed to pursue a "mutually beneficial relationship based on common strategic interests" designed to ensure frequent leadership exchanges on issues such as security and economic cooperation. On the sidelines of the APEC summit, Kishida has also met South Korean President Yoon Suk Yeol for their seventh meeting this year. Leaders from the 21-member Asia-Pacific Economic Cooperation forum are in San Francisco for its 30th summit from Nov. 15-17.

Persons: Fumio Kishida, Xi Jinping, Carlos Barria, Xi, Kishida, Joe Biden, Biden, Washington, Rumi Aoyama, Aoyama, Yoon Suk, Yoon, Mariko Katsumura, John Geddie, Kaori Kaneko, Sakura Murakami, Ethan Wang, Stephen Coates, Raju Gopalakrishnan Organizations: Japan's, Economic Cooperation, REUTERS, Asia, Astellas Pharma, ., Waseda Institute of Contemporary Chinese, APEC, South, Thomson Locations: Asia, San Francisco , California, U.S, China, San Francisco, Japan, Taiwan, Beijing, United States, Tokyo

☆ Eli Lilly plans to invest 2 bln euros in new German plant -source
▼ + stars: | 2023-11-16 | by ( ) www.reuters.com time to read: +1 min

An Eli Lilly and Company pharmaceutical manufacturing plant is pictured at 50 ImClone Drive in Branchburg, New Jersey, March 5, 2021. REUTERS/Mike Segar/File Photo Acquire Licensing RightsCompanies Eli Lilly and Co FollowBERLIN, Nov 16 (Reuters) - U.S. pharma company Eli Lilly (LLY.N) plans to invest 2 billion euros ($2.17 billion) in a new plant in Alzey, western Germany, a source close to the negotiations told Reuters on Thursday. Separately, people familiar with the plans told Reuters that at least 1,000 jobs would be created. Reuters had reported on Wednesday that the pharma group intended to invest in Germany after Eli Lilly called a news conference for Friday but few details were available. ($1 = 0.9217 euros)Reporting by Andreas Rinke and Rene Wagner Writing by Madeline Chambers Editing by Kirsti Knolle and Miranda MurrayOur Standards: The Thomson Reuters Trust Principles.

Persons: Eli Lilly, Mike Segar, Andreas Rinke, Rene Wagner, Madeline Chambers, Kirsti Knolle, Miranda Murray Organizations: Company, REUTERS, . pharma, Reuters, pharma, Thomson Locations: Branchburg , New Jersey, Alzey, Germany

FDA officials don't have the legal authority to force manufacturers to recall their products, and instead rely on companies to “voluntarily” do so. The FDA previously stated it recommended the manufacturer recall the eyedrops on Oct. 25. That suggests agency officials may still be finalizing documentation from the inspection that triggered the latest recall. Agency records show FDA didn't conduct any inspections in India during fiscal year 2021, at the height of the pandemic. CVS Health said in a statement that it previously “stopped the sale in-store and online” of all the eyedrops cited by the FDA.

Persons: “, weren't Organizations: WASHINGTON, CVS Health, Target, Rite, Kilitch Healthcare, Food and Drug Administration, FDA, Healthcare, U.S, Velocity Pharma, Agency, COVID, CVS, Cardinal Health, Delsam Pharma, Centers for Disease Control, CDC, Associated Press Health, Science Department, Howard Hughes Medical Institute’s Science, Educational Media Group, AP Locations: U.S, Kilitch Healthcare India, Mumbai, Farmingdale, N.Y, India, India’s, Tamil Nadu

An Eli Lilly and Company pharmaceutical manufacturing plant is pictured at 50 ImClone Drive in Branchburg, New Jersey, March 5, 2021. REUTERS/Mike Segar/File Photo Acquire Licensing RightsBERLIN, Nov 15 (Reuters) - U.S. pharma company Eli Lilly (LLY.N) plans an investment in the single-digit billion dollar range in a new plant in western Germany, people familiar with the matter told Reuters after the company called a news conference for Friday. Eli Lilly said it would unveil "far-reaching investment plans" at Friday's news conference, which will be attended by Germany's economy and health ministers. Mounjaro's success helped Lilly post a 37% gain in third-quarter revenues to $9.5 billion, topping Wall Street estimates. The group's market value has ballooned to around $580 billion, up more than 65% so far this year.

Persons: Eli Lilly, Mike Segar, Mounjaro, TSMC, Lilly's, Lilly, Rene Wagner, Klaus Lauer, Ludwig Burger, Thomas Escritt, Chizu Nomiyama, Jane Merriman Organizations: Company, REUTERS, Rights, . pharma, Reuters, U.S ., U.S, Intel, European Union, Novo Nordisk, U.S . Food, Drug Administration, Thomson Locations: Branchburg , New Jersey, Germany, Rhineland, Palatinate, U.S, Ukraine, European, Indianapolis, Danish, Eisai

TOKYO, Nov 15 (Reuters) - Visitors to Japan exceeded pre-pandemic levels in October, official data showed on Wednesday, marking a full recovery in arrivals for the first time since the relaxation of border controls last year. The number of foreign visitors for business and leisure rose to 2.52 million last month from 2.18 million in September, data from the Japan National Tourism Organization (JNTO) showed. Reuters GraphicsVisitor numbers improved to 100.8% of levels seen in 2019 before the outbreak of COVID-19 led to travel curbs around the world. That year, Chinese accounted for nearly a third of all visitors and 40% of all tourist spending in Japan. Almost 20 million visitors have arrived in Japan in the first 10 months of 2023, JNTO data showed, compared to the record of about 32 million in all of 2019.

Persons: Rocky Swift, Miral Organizations: Visitors, Japan National Tourism Organization, Graphics, Thomson Locations: TOKYO, Japan, Southeast Asia, North America, Europe, Australia, Canada, Mexico, Germany, China

China detained the executive, named in several media reports as Hiroshi Nishiyama, on suspicion of espionage in March, and he was formally arrested last month. Japan's then foreign minister protested the executive's detention with his Chinese counterpart on a visit to Beijing in April. China's foreign ministry did not immediately respond to a request for comment. Half the respondents in a recent survey of Japanese companies doing business in China said they would cut investments this year. It's a very difficult point in time to be navigating that as a decision maker, in business or politics," he said.

Persons: Fumio Kishida, Xi Jinping, Rahm Emanuel, Hiroshi Nishiyama, Japan's, Xi, Masashi Mizobuchi, Nishiyama, Takeshi Niinami, Niinami, Stefan Angrick, Yukiko Toyoda, Kiyoshi Takenaka, John Geddie, Sakura Murakami, Francis Tang, Laurie Chen, Antoni Slodkowski, Andrew Silver, Lincoln Organizations: Economic Cooperation, Kyodo, drugmaker Astellas Pharma, APEC, Reuters, Japanese Chamber of Commerce, Japan Association of Corporate, Suntory, Moody's Analytics, Thomson Locations: Asia, Bangkok, Thailand, TOKYO, BEIJING, China, San Francisco, Tokyo, U.S, Japan, Beijing, officialdom, Shanghai

☆ Investors are the most overweight bonds in 14 years, expecting rates to decline, survey shows
▼ + stars: | 2023-11-14 | by ( Jeff Cox | ) www.cnbc.com time to read: +2 min

Professional investors are flocking to bonds in a stampede not seen since the end of the financial crisis, according to the latest Bank of America Global Fund Manager Survey. "The big change in the November FMS was not the macro outlook, but rather the conviction in lower inflation, rates, and yields," Bank of America investment strategist Michael Hartnett wrote in a summary of the results. The move was "evidenced by the 3rd largest overweight in bonds in the last two decades (only in Mar'09 and Dec'08 were investors more overweight bonds)." Expectations for a bond reversal dominated the November survey, with a record 61% saying they expect lower yields over the next 12 months. The "investor playbook for 2024 is soft landing, lower rates, weaker US$, large cap tech and pharma bull continues, avoid China and leverage," Hartnett said.

Persons: Michael Hartnett, playbook, Hartnett Organizations: Bank of America Global Fund, Survey, Wall Street, Bank of America, Mar, Federal Reserve, pharma Locations: China

☆ Weight-loss drugs just got cheaper — and better
▼ + stars: | 2023-11-11 | by ( Hilary Brueck | ) www.businessinsider.com time to read: +7 min

Eli Lilly just debuted its powerful new weight-loss drug, Zepbound. Normally, when newer, better drugs are introduced, they match the price of similar drugs already available or come at a premium . Eli Lilly and Novo Nordisk have said that about 50 million people have some level of insurance coverage for weight-loss drugs. But some experts were skeptical, because employers and insurers don't typically pay the list price for drugs. Craig Garthwaite, an economist at Northwestern University, argued competition will drive the net prices of weight-loss drugs lower still.

Persons: Eli Lilly, —, Wegovy, LLY, It's, Mike Mason, coinsurance, Antonio Ciaccia, Crystal, We're, David Risinger, Dave Ricks, David Ricks, Eli Lilly's Mason, Mason, Craig Garthwaite, Garthwaite Organizations: Service, pharma, Nordisk's Wegovy, Ozempic, Deutsche Bank, 46brooklyn Research, Crystal Cox, Novo Nordisk, Zepbound, Wegovy, American Enterprise Institute, Northwestern University Locations: Mounjaro

☆ Wegovy Maker Novo Nordisk to Spend $6 Billion Boosting Production Capacity
▼ + stars: | 2023-11-10 | by ( Dominic Chopping | ) www.wsj.com time to read: 1 min

This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com. https://www.wsj.com/health/pharma/novo-nordisk-invests-over-6-bln-to-boost-production-capacity-f01c9d74

Persons: Dow Jones Organizations: pharma, nordisk

☆ Lilly trades at a premium to Ozempic-maker Novo as obesity drugs boom. Here's why, analyst says
▼ + stars: | 2023-11-10 | by ( Christina Cheddar Berk | ) www.cnbc.com time to read: +6 min

Does Eli Lilly deserve to trade at a premium to Novo Nordisk shares? LLY YTD mountain Eli Lilly shares since the start of the year. According to Shin, Lilly deserves a premium to Novo Nordisk because its portfolio is more diverse and it has less exposure to insulin. NVO YTD mountain Novo Nordisk shares year to date In the coming weeks, Lilly will start rolling out Zepbound to patients. Novo Nordisk is scheduled to release the full results of its Select cardiovascular trial at the American Heart Association conference.

Persons: Eli Lilly, James Shin, Shin, Lilly, We're, Lilly's, Zepbound, Wegovy, Chris Schott, Karsten Munk Knudsen, Novo, Schott, AstraZeneca, Eccogene, David Ricks, — CNBC's Michael Bloom Organizations: Novo Nordisk, Deutsche Bank, Biotech, Pharma, Centers for Disease Control, Novo, CNBC, American Heart Association Locations: U.S, GLP, Novo, Denmarkt

Search resuls for: "PHARMA"

25 mentions found